Tiotropium

What it is

An inhaled bronchodilator taken once a day. It comes in two quite different devices that matter for the evidence: the HandiHaler, a dry-powder inhaler that delivers 18 micrograms from a capsule, and the Respimat, a propellant-free soft-mist inhaler that delivers 2.5 or 5 micrograms as a spray. Chemically it is a quaternary ammonium derivative structurally related to atropine. The HandiHaler capsule formulation contains lactose, so it carries a caution for severe milk-protein allergy.

What the research says

It opens the airways by blocking muscarinic receptors on airway smooth muscle, and the block lasts more than 24 hours, which is why it is a once-daily drug. In COPD the evidence is strong for better lung function, better quality of life and fewer exacerbations: a Cochrane review of 22 trials in 23,309 people found a number needed to treat of 16 for a year to prevent one person having an exacerbation. It does not slow the long-term decline of lung function - the 4-year UPLIFT trial missed both co-primary endpoints on that question. In asthma, as an add-on to inhaled steroids with or without a long-acting beta-agonist, it gives modest extra lung function and in two replicate trials cut the risk of a severe exacerbation by 21 percent, but Cochrane found the effect on oral-steroid-requiring exacerbations imprecise and the quality-of-life gain negligible. The mortality story needs both halves: a 2011 meta-analysis found a 52 percent higher death rate with the Respimat soft-mist inhaler versus placebo, and the 17,135-patient TIOSPIR trial then found Respimat non-inferior to HandiHaler for death.

Evidence grade: Well established.

How it works

Drug class: Long-acting muscarinic antagonist (LAMA), also called a long-acting anticholinergic bronchodilator; an inhaled atropine-like agent

Airway muscle is held partly tightened by acetylcholine acting on muscarinic receptors. Tiotropium binds those receptors and blocks acetylcholine, mainly at the M3 subtype on smooth muscle, which lets the airways relax and widen. The block comes off slowly, so one inhalation keeps working beyond 24 hours. Because it is inhaled, most of the effect is local to the lung - but the anticholinergic effects that do reach the rest of the body (dry mouth, constipation, urinary retention, raised eye pressure) are the same class effects as atropine. (Source 1)

What it is used for

• A Cochrane review of 22 trials in 23,309 people found better quality of life, fewer people having exacerbations (OR 0.78, 95% CI 0.70 to 0.87; NNT 16 for a year) and trough FEV1 about 119 mL higher than placebo. The 6-month Veterans Affairs trial cut the proportion with an exacerbation from 32.3 percent to 27.9 percent. Evidence: established. (Source 2)
• This was the explicit question UPLIFT was built to answer in 5,993 patients over 4 years, and it failed: after day 30 the difference between tiotropium and placebo in the rate of FEV1 decline was not significant for either co-primary endpoint. The label records the same result. Evidence: not-supported. (Source 3)
• In two replicate 48-week trials in 912 people already on inhaled steroids plus a long-acting beta-agonist, tiotropium raised peak FEV1 by 86 and 154 mL and cut the risk of a severe exacerbation by 21 percent (HR 0.79, p=0.03). Cochrane's pooled analysis of four such trials found the reduction in oral-steroid-requiring exacerbations imprecise (OR 0.76, 95% CI 0.57 to 1.02) with high-quality evidence only for the lung-function gain. Evidence: established. (Source 4)
• The label states safety and efficacy have not been established under 6. One 12-week placebo-controlled safety study in 70 children aged 1 to 5 using a valved holding chamber reported an adverse-reaction profile similar to older patients, but that is a safety study, not an efficacy result. Evidence: unknown. (Source 5)
• Cochrane found exactly one eligible randomised trial, a 210-patient crossover study against double-dose beclomethasone. Differences were too small or imprecise to say whether adding a LAMA is safer or more effective than raising the steroid dose; the FEV1 advantage was about 100 mL on moderate-quality evidence. Evidence: unknown. (Source 6)
• The label states explicitly that it is a once-daily maintenance treatment and should not be used as rescue therapy for acute bronchospasm; onset takes hours and in asthma maximum benefit can take 4 to 8 weeks. Evidence: not-supported. (Source 7)

Interactions

• Other anticholinergic medicines (ipratropium, oxybutynin and other bladder antimuscarinics, tricyclic antidepressants, sedating antihistamines such as diphenhydramine, scopolamine) (label): The anticholinergic effects add up - more dry mouth, constipation, blurred vision, difficulty passing urine and raised eye pressure. The label says to avoid taking tiotropium with other anticholinergic-containing drugs. (Source 8)
• Beta-agonist inhalers (salbutamol, salmeterol, formoterol), theophylline and other methylxanthines, and oral or inhaled steroids (label): These are routinely used alongside tiotropium. The label reports no increase in adverse reactions when they were given together in the trials - this is one of the interactions that does not appear to exist. (Source 9)
• Lactose and milk protein (the HandiHaler capsule excipient) (label): The dry-powder capsules are blended with lactose, which carries milk protein. The label says the product should be used with caution in people with severe hypersensitivity to milk proteins. This is a formulation issue with the HandiHaler, not with the Respimat spray. (Source 10)
• Alcohol (label): No interaction with alcohol is documented in the label's drug interactions sections, which name only anticholinergics and the respiratory medicines above, and we found none in the Cochrane review or the large trials. Treat this as an absence of evidence rather than a demonstrated absence of effect. (Source 8)
• Supplements (St John's wort, grapefruit, calcium, iron, magnesium, potassium, vitamin K, fish oil, turmeric, red yeast rice) (label): We found no documented interaction for any of these with tiotropium. That is mechanistically unsurprising for an inhaled quaternary ammonium compound that is predominantly renally excreted rather than cleared by the cytochrome P450 enzymes those supplements affect. The label's own interaction sections list only anticholinergics and the respiratory medicines; the one renal caution it gives is about kidney function, not supplements. (Source 1)

Stopping it

• There is no dependence or withdrawal syndrome described for tiotropium in the trials or the Cochrane review. What the evidence does show is that the benefit is present while the drug is taken: the Cochrane review's lung-function result is a difference measured at the end of treatment, not a lasting change in the disease. (Source 2)
• UPLIFT is the cleanest evidence that stopping does not leave the lung-function trajectory altered: over 4 years the slope of FEV1 decline was the same on drug and placebo, so the absolute 87 to 103 mL gain is a bronchodilator effect that stops when the drug stops rather than disease modification banked for later. (Source 11)
• If an immediate hypersensitivity reaction or paradoxical bronchospasm occurs, the label's instruction is to stop the drug at once rather than taper it, and to treat paradoxical bronchospasm with a short-acting beta-agonist. (Source 7)
• In the trials people on tiotropium were less likely than people on placebo to drop out, which the Cochrane authors flag as a limitation rather than a benefit, because the uneven discontinuation makes the mortality comparison harder to read. (Source 2)

What goes wrong

A meta-analysis of five randomised placebo-controlled trials in people with COPD found a 52 percent higher risk of death with tiotropium delivered by the Respimat soft-mist inhaler than with placebo. (Source 12)

• Meta-analysis, Moderate certainty.
• Size: 5 randomised controlled trials; 90 deaths in 3,686 on tiotropium versus 47 in 2,836 on placebo.
• Who: people with COPD on tiotropium Respimat versus placebo for more than 30 days.
• How long: trial durations over 30 days, including three one-year trials.
• Result: all-cause mortality relative risk 1.52 (95% CI 1.06 to 2.16; P=0.02; I2=0%); 10 µg dose RR 2.15 (1.03 to 4.51); 5 µg dose RR 1.46 (1.01 to 2.10); number needed to treat for a year to cause one additional death estimated at 124 (95% CI 52 to 5682)
• Funding: no company support for the submitted work; one author disclosed about $30,000 from Pfizer for unrelated spirometry review; NIH NCRR support listed.

Limit of this finding: This is tiotropium Respimat in COPD, measured against placebo. It is a separate body of evidence from the tiotropium asthma trials reported elsewhere in this entry, and the two should not be read together. The later TIOSPIR trial compared Respimat against the HandiHaler rather than against placebo, so it does not directly overturn this result.

Tiotropium mist inhaler was associated with a significantly increased risk of mortality (90/3686 v 47/2836; relative risk 1.52, 95% confidence interval, 1.06 to 2.16; P = 0.02; I(2) = 0%). Both 10 µg (2.15, 1.03 to 4.51; P = 0.04; I(2) = 9%) and 5 µg (1.46, 1.01 to 2.10; P = 0.04; I(2) = 0%) doses of tiotropium mist inhaler were associated with an increased risk of mortality. The overall estimates were not substantially changed by sensitivity analysis of the fixed effect analysis of the five trials combined using the random effects model (1.45, 1.02 to 2.07; P = 0.04), limiting the analysis to three trials of one year's duration each (1.50, 1.05 to 2.15), or the inclusion of additional data on tiotropium mist inhaler from another investigational drug programme (1.42, 1.01 to 2.00). The number needed to treat for a year with the 5 µg dose to see one additional death was estimated to be 124 (95% confidence interval 52 to 5682) based on the average control event rate from the long term trials. CONCLUSIONS: This meta-analysis explains safety concerns by regulatory agencies and indicates a 52% increased risk of mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease.

An earlier meta-analysis of inhaled anticholinergics as a class found a significantly increased risk of cardiovascular death, myocardial infarction or stroke. (Source 13)

• Meta-analysis, Low certainty.
• Size: 17 trials, 13,645 patients (134 events in 6,984 on anticholinergics versus 83 in 6,661 on control)
• Who: people with COPD in randomised trials of ipratropium or tiotropium lasting at least 30 days.
• How long: follow-up 6 weeks to 5 years.
• Result: composite of cardiovascular death, MI or stroke 1.9% versus 1.2%, RR 1.60 (95% CI 1.22-2.10; P<.001; I2=0%); MI RR 1.52 (1.04-2.22); cardiovascular death RR 1.92 (1.23-3.00); stroke RR 1.46 (0.81-2.62), not significant; all-cause mortality 2.1% versus 1.6%, RR 1.29 (1.00-1.65; P=.05); long-term trials only 2.9% versus 1.8%, RR 1.73 (1.27-2.35)
• Funding: not stated in the abstract.

Limit of this finding: The quotation keeps the "[corrected]" markers exactly as they appear in the published abstract. They are the journal’s own erratum markers, flagging figures that were amended after publication, and are not stray characters or transcription noise. The analysis also pools ipratropium with tiotropium, so it is a class result rather than a tiotropium-specific one.

Cardiovascular death, MI, or stroke occurred in 134 of 6984 [corrected] patients (1.9%) [corrected] receiving inhaled anticholinergics and 83 of 6661 [corrected] patients (1.2%) receiving control therapy (RR, 1.60 [corrected] [95% confidence interval {CI}, 1.22-2.10]; [corrected] P < .001, I(2) = 0%). Among individual components of the primary end point, inhaled anticholinergics significantly increased the risk of MI (RR, 1.52 [95% CI 1.04-2.22]; [corrected] P = .03, I(2) = 0%) and cardiovascular death (RR, 1.92 [95% CI, 1.23-3.00]; P = .004, [corrected] I(2) = 0%) without a statistically significant increase in the risk of stroke (RR, 1.46 [95% CI, 0.81-2.62]; P = .20, I(2) = 0%).

In the manufacturer’s one-year COPD trials the label’s Table 1 reports adverse reactions as a percentage of patients: dry mouth 16 percent on tiotropium versus 3 percent on placebo, and constipation 4 versus 2 percent. (Source 14)

• Randomized trial, Moderate certainty.
• Size: placebo-controlled trials: 550 on tiotropium, 371 on placebo (table rows); safety database 2,663 patients overall.
• Who: people with COPD aged 39-87; those with narrow-angle glaucoma, symptomatic prostatic hypertrophy or bladder outlet obstruction were excluded.
• How long: 6 months to 1 year.
• Result: dry mouth 16% versus 3% placebo (and 12% versus 6% in the ipratropium-controlled trials); constipation 4% versus 2%; vomiting 4% versus 2%; sinusitis 11% versus 9%; urinary tract infection 7% versus 5%; epistaxis 4% versus 2%.
• Funding: manufacturer trials reported in the FDA label.

Table 1 Adverse Reactions (% Patients) in One-Year COPD Clinical Trials Body System (Event) | Placebo-Controlled Trials | Ipratropium-Controlled Trials | SPIRIVA (n = 550) | Placebo (n = 371) | SPIRIVA (n = 356) | Ipratropium (n = 179) Body as a Whole Chest Pain (non-specific) | 7 | 5 | 5 | 2 Edema, Dependent | 5 | 4 | 3 | 5 Gastrointestinal System Disorders Dry Mouth | 16 | 3 | 12 | 6 Dyspepsia | 6 | 5 | 1 | 1 Abdominal Pain | 5 | 3 | 6 | 6 Constipation | 4 | 2 | 1 | 1

In the 4-year trial the drug-versus-placebo rates for the commonest reactions were lower but still consistently above placebo, including dry mouth 5.1 versus 2.7 percent and depression 4.4 versus 3.3 percent. (Source 15)

• Randomized trial, Moderate certainty.
• Size: 5,992 COPD patients, 2,986 on tiotropium 18 mcg once daily.
• Who: people with COPD aged 40-88, 75% male, mean pre-bronchodilator FEV1 40% predicted; narrow-angle glaucoma and bladder outlet obstruction excluded.
• How long: 4 years.
• Result: tiotropium versus placebo: pharyngitis 12.5% vs 10.8%, sinusitis 6.5% vs 5.3%, headache 5.7% vs 4.5%, constipation 5.1% vs 3.7%, dry mouth 5.1% vs 2.7%, depression 4.4% vs 3.3%, insomnia 4.4% vs 3.0%, arthralgia 4.2% vs 3.1%.
• Funding: manufacturer trial reported in the FDA label.

adverse reactions included (SPIRIVA HANDIHALER, placebo): pharyngitis (12.5%, 10.8%), sinusitis (6.5%, 5.3%), headache (5.7%, 4.5%), constipation (5.1%, 3.7%), dry mouth (5.1%, 2.7%), depression (4.4%, 3.3%), insomnia (4.4%, 3.0%), and arthralgia (4.2%, 3.1%).

In the asthma trials the drug-versus-placebo adverse reaction rates were pharyngitis 15.9 versus 12.4 percent, bronchitis 3.3 versus 1.4 percent, sinusitis 2.7 versus 1.4 percent and headache 3.8 versus 2.7 percent. (Source 16)

• Randomized trial, Moderate certainty.
• Size: 2,849 asthma patients across four placebo-controlled trials; 787 on the recommended 2.5 mcg dose versus 735 on placebo.
• Who: adults aged 18-75 with asthma on at least an inhaled corticosteroid, or an inhaled corticosteroid plus a long-acting beta-agonist; mean age 43.7, mean post-bronchodilator FEV1 90% predicted.
• How long: 12 weeks to 1 year.
• Result: pharyngitis 125 (15.9%) versus 91 (12.4%); sinusitis 21 (2.7%) versus 10 (1.4%); bronchitis 26 (3.3%) versus 10 (1.4%); headache 30 (3.8%) versus 20 (2.7%); dizziness, oropharyngeal candidiasis, diarrhoea, cough, allergic rhinitis, urinary tract infection, pyrexia and hypertension each 1% to 2% and higher than placebo.
• Funding: manufacturer trials reported in the FDA label.

Table 2 Number (Percentage) of Asthma Patients Exposed to SPIRIVA RESPIMAT 2.5 mcg with Adverse Reactions >2% (and Higher than Placebo): Pooled Data from 4 Adult Clinical Trials with Treatment Periods Ranging between 12 and 52 Weeks in Asthma Patients Body System (Reaction)* | SPIRIVA RESPIMAT 2.5 mcg [n=787] | Placebo [n=735] *Adverse reactions include a grouping of similar terms Respiratory, Thoracic, and Mediastinal Disorders | | Pharyngitis | 125 (15.9) | 91 (12.4) Sinusitis | 21 (2.7) | 10 (1.4) Bronchitis | 26 (3.3) | 10 (1.4) Nervous System Disorders | | Headache | 30 (3.8) | 20 (2.7)

Tiotropium carries the class risks of an inhaled anticholinergic in the eye and bladder, which is why the registration trials excluded people with narrow-angle glaucoma or bladder outlet obstruction. (Source 17)

• Official position, Certainty not rated.
• Size: not applicable (label warning)
• Who: people with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.
• How long: not applicable.
• Result: no rate given; the label instructs prescribers and patients to watch for eye pain, blurred vision, visual halos or coloured images with red eyes, and for difficulty or pain passing urine; raised intraocular pressure and urinary retention also appear in postmarketing reports.
• Funding: label position of the manufacturer as approved by FDA, version effective 10 November 2025.

Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

What the evidence supports

A Cochrane review of 22 trials found tiotropium improved quality of life and reduced the number of people having COPD exacerbations, with a number needed to treat of 16 over a year. (Source 2)

• Systematic review, Moderate certainty.
• Size: 22 studies, 23,309 participants.
• Who: people with stable COPD; 19 trials used 18 mcg HandiHaler, 3 used 5 or 10 mcg Respimat.
• How long: three months to four years.
• Result: St George's Respiratory Questionnaire mean difference -2.89 (95% CI -3.35 to -2.44); clinically significant improvement OR 1.52 (1.38 to 1.68); participants with an exacerbation OR 0.78 (0.70 to 0.87), NNT 16 (95% CI 10 to 36) against a placebo event rate of 44%; trough FEV1 MD 118.92 mL (113.07 to 124.77)
• Funding: Cochrane review; UK Department of Health support declared for the 2014 update; authors declared none known.

Tiotropium treatment significantly reduced the number of participants suffering from exacerbations (OR 0.78; 95% CI 0.70 to 0.87). This corresponds to a need to treat 16 patients (95% CI 10 to 36) with tiotropium for a year in order to avoid one additional patient suffering exacerbations, based on the average placebo event rate of 44% from one-year studies.

Two replicate 48-week trials of tiotropium added to inhaled steroids plus a long-acting beta-agonist, in adults with poorly controlled ASTHMA, improved lung function and cut the risk of a severe exacerbation by 21 percent. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 912 patients across two replicate trials.
• Who: symptomatic adults (mean age 53) on inhaled glucocorticoids and LABAs, post-bronchodilator FEV1 80% predicted or less, at least one severe exacerbation in the previous year.
• How long: 48 weeks.
• Result: peak FEV1 difference 86±34 mL in trial 1 (P=0.01) and 154±32 mL in trial 2 (P<0.001); trough FEV1 88±31 mL (P=0.01) and 111±30 mL (P<0.001); time to first severe exacerbation 282 days versus 226 days, hazard ratio 0.79, 21% risk reduction (P=0.03); no deaths, adverse events similar.
• Funding: funded by Boehringer Ingelheim and Pfizer (NCT00772538, NCT00776984)

Limit of this finding: This evidence is in asthma, not COPD. The statement that no deaths occurred applies only to these two 48-week asthma trials and says nothing about the separate COPD mortality signal reported for the Respimat inhaler elsewhere in this entry.

The addition of tiotropium increased the time to the first severe exacerbation (282 days vs. 226 days), with an overall reduction of 21% in the risk of a severe exacerbation (hazard ratio, 0.79; P=0.03). No deaths occurred; adverse events were similar in the two groups. CONCLUSIONS: In patients with poorly controlled asthma despite the use of inhaled glucocorticoids and LABAs, the addition of tiotropium significantly increased the time to the first severe exacerbation and provided modest sustained bronchodilation.

In the 4-year placebo-controlled trial, exacerbations were a secondary outcome and tiotropium cut the risk of an exacerbation and of exacerbation-related hospitalisation by 14 percent each. (Source 18)

• Randomized trial, Moderate certainty.
• Size: 5,992 COPD patients in the 4-year multicentre trial.
• Who: people with COPD aged 40-88 permitted all respiratory medicines except inhaled anticholinergics.
• How long: 4 years.
• Result: risk of an exacerbation reduced by 14% (HR 0.86; 95% CI 0.81, 0.91; p<0.001); risk of exacerbation-related hospitalisation reduced by 14% (HR 0.86; 95% CI 0.78, 0.95; p<0.002); median time to first exacerbation 12.5 months on placebo versus 16.7 months on tiotropium.
• Funding: manufacturer trial reported in the FDA label.

Limit of this finding: Exacerbations were a secondary, not a primary, outcome of this 4-year trial, whose two co-primary endpoints on the rate of lung-function decline were both missed.

Exacerbations were evaluated as a secondary outcome in the 4-year multicenter trial. In this trial, COPD exacerbations were defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea) with a duration of three or more days requiring treatment with antibiotics and/or systemic (oral, intramuscular, or intravenous) steroids. SPIRIVA HANDIHALER significantly reduced the risk of an exacerbation by 14% (Hazard Ratio (HR) = 0.86; 95% CI = 0.81, 0.91; p<0.001) and reduced the risk of exacerbation-related hospitalization by 14% (HR = 0.86; 95% CI = 0.78, 0.95; p<0.002) compared to placebo.

What the evidence does not support

In the 4-year UPLIFT trial, tiotropium did not slow the rate of decline in lung function - it missed both co-primary endpoints. (Source 3)

• Randomized trial, High certainty.
• Size: 5,993 patients randomised (2,987 tiotropium, 3,006 placebo)
• Who: people aged 40 and over with COPD, FEV1 70% or less after bronchodilation; all respiratory medicines permitted except inhaled anticholinergics.
• How long: 4 years.
• Result: after day 30 the differences in rate of decline in mean FEV1 before and after bronchodilation were not significant; absolute FEV1 improvements were maintained (87-103 mL pre-bronchodilator, 47-65 mL post, P<0.001) and SGRQ was better by 2.3 to 3.3 units.
• Funding: manufacturer-sponsored trial (Boehringer Ingelheim; NCT00144339), reported as research support, non-US government.

After day 30, the differences between the two groups in the rate of decline in the mean FEV(1) before and after bronchodilation were not significant. The mean absolute total score on the SGRQ was improved (lower) in the tiotropium group, as compared with the placebo group, at each time point throughout the 4-year period (ranging from 2.3 to 3.3 units, P<0.001). At 4 years and 30 days, tiotropium was associated with a reduction in the risks of exacerbations, related hospitalizations, and respiratory failure. CONCLUSIONS: In patients with COPD, therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1).

TIOSPIR was a randomised, double-blind, parallel-group trial in 17,135 people with COPD that compared the Respimat soft-mist inhaler head to head against the HandiHaler dry-powder inhaler, with no placebo arm: death was tested for noninferiority and first exacerbation for superiority, and Respimat was noninferior for death and not superior for exacerbation. (Source 19)

• Randomized trial, High certainty.
• Size: 17,135 patients with COPD.
• Who: people with COPD, including patients with stable cardiac disease.
• How long: mean follow-up 2.3 years.
• Result: death: Respimat 5 µg versus HandiHaler hazard ratio 0.96 (95% CI 0.84 to 1.09); Respimat 2.5 µg versus HandiHaler 1.00 (0.87 to 1.14); first exacerbation Respimat 5 µg versus HandiHaler 0.98 (0.93 to 1.03); causes of death and major cardiovascular adverse event incidences similar across the three groups.
• Funding: funded by Boehringer Ingelheim (NCT01126437)

Limit of this finding: The two endpoints were tested against different standards, and that matters for reading the result. "Noninferior" for death means the trial could not show Respimat was worse than HandiHaler; it is not a test against placebo and so does not speak to the earlier placebo-controlled mortality signal. "Not superior" for exacerbation means the trial set out to show Respimat was better and did not. The comparator throughout was another tiotropium inhaler, so the trial answers a different question from the placebo-controlled meta-analysis.

In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler). We also assessed cardiovascular safety, including safety in patients with stable cardiac disease. RESULTS: During a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 μg vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03). Causes of death and incidences of major cardiovascular adverse events were similar in the three groups.

Against raising the inhaled steroid dose instead, the single eligible trial was too small and imprecise to show whether adding tiotropium is better or safer. (Source 6)

• Systematic review, Low certainty.
• Size: one crossover randomised trial, 210 patients.
• Who: adults with moderate to severe asthma not well controlled on inhaled corticosteroid alone, not taking long-acting beta-agonists.
• How long: 14-week treatment periods in a crossover design.
• Result: exacerbation requiring oral corticosteroids OR 0.57 (95% CI 0.22 to 1.43); emergency department admission OR 0.49 (0.09 to 2.77); asthma quality of life mean difference 0.10 (95% CI -0.07 to 0.27), low quality; asthma control MD -0.18 (-0.34 to -0.02), clinically small, low quality; trough FEV1 100 mL better, MD 0.10 (0.03 to 0.17), moderate quality.
• Funding: Cochrane review, UK Department of Health support; authors none known.

Differences between the treatments were too small or imprecise to understand whether adding a LAMA to ICS is safer or more effective than increasing the dose of ICS, and there is a possibility of carry-over effects due to the study's cross-over design. LAMA add-on may lead to more improvement in lung function (FEV1) than an increased dose of ICS.

Where the evidence is mixed

Within the Cochrane review the mortality result split by device: no overall difference, fewer deaths with the dry-powder inhaler, and significantly more with the soft-mist inhaler. (Source 2)

• Systematic review, Moderate certainty.
• Size: 22 studies, 23,309 participants.
• Who: people with stable COPD.
• How long: three months to four years.
• Result: all-cause mortality overall Peto OR 0.98 (95% CI 0.86 to 1.11), no significant difference; subgroup difference by device P=0.01; dry powder inhaler Peto OR 0.92 (0.80 to 1.05) against a placebo yearly rate of 2.8%; soft mist inhaler Peto OR 1.47 (1.04 to 2.08) against a placebo yearly rate of 1.8%; the review notes discontinuation rates were uneven (OR 0.66, 0.59 to 0.73)
• Funding: Cochrane review, UK Department of Health support.

Additionally, there was no statistically significant difference in all-cause mortality between the tiotropium and placebo groups (Peto OR 0.98; 95% CI 0.86 to 1.11). However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: P = 0.01). With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92; 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%).

Cochrane found only four eligible trials and 1,197 people with severe asthma on a steroid-plus-LABA inhaler - and only three of those trials, all of tiotropium, contributed data - with the reduction in oral-steroid-requiring exacerbations not reaching significance, no meaningful quality-of-life gain, and inconsistent serious-adverse-event data. (Source 20)

• Systematic review, Moderate certainty.
• Size: four double-blind, double-dummy trials, 1,197 people with asthma on LABA/ICS; one trial (glycopyrronium) was withdrawn before enrolment, so only three trials, all of tiotropium bromide, contributed data.
• Who: adults with severe asthma, mean FEV1 55% predicted.
• How long: 48 to 52 weeks.
• Result: exacerbations requiring oral corticosteroids OR 0.76 (95% CI 0.57 to 1.02), moderate quality; over 48 weeks 328 per 1,000 on LABA/ICS alone versus 271 per 1,000 with tiotropium (95% CI 218 to 333); AQLQ mean difference 0.09 (95% CI -0.03 to 0.20) against a 0.5 minimal clinically important difference; serious adverse events OR 0.60 (0.24 to 1.47), I2=76%; high-quality evidence for trough FEV1 and FVC.
• Funding: Cochrane review, UK Department of Health support; authors declared none known.

We found four double-blind, double-dummy trials comparing LAMA to placebo, including 1197 people with asthma taking combination LABA/ICS. One of the trials was designed to study glycopyrronium bromide but was withdrawn prior to enrolment, and the other three all studied tiotropium bromide (mostly 5 µg once daily via Respimat) over 48 to 52 weeks. People in the trials had a mean forced expiratory volume in one second (FEV1) of 55% of their predicted value, indicating severe asthma.People randomised to take tiotropium add-on had fewer exacerbations requiring oral corticosteroids than those continuing to take LABA/ICS alone, but the confidence intervals did not rule out no difference (OR 0.76, 95% CI 0.57 to 1.02; moderate quality evidence). Over 48 weeks, 328 out of 1000 people taking their usual LABA/ICS would have to take oral corticosteroids for an exacerbation compared with 271 if they took tiotropium as well (95% CI 218 to 333 per 1000).

In the 6-month Veterans Affairs trial the absolute reduction in exacerbations was 4.4 percentage points, and the reduction in exacerbation hospitalisations did not reach significance. (Source 18)

• Randomized trial, Moderate certainty.
• Size: 1,829 COPD patients.
• Who: people aged 40-90 in a US Veterans Affairs setting, 99% male, mean pre-bronchodilator FEV1 36% predicted.
• How long: 6 months.
• Result: proportion with an exacerbation 27.9% versus 32.3%, odds ratio 0.81 (95% CI 0.66, 0.99; p=0.037); hospitalisation due to exacerbation 7.0% versus 9.5%, OR 0.72 (95% CI 0.51, 1.01; p=0.056)
• Funding: manufacturer trial reported in the FDA label.

SPIRIVA HANDIHALER significantly reduced the proportion of COPD patients who experienced exacerbations compared to placebo (27.9% vs. 32.3%, respectively; Odds Ratio (OR) (tiotropium/placebo) = 0.81; 95% CI = 0.66, 0.99; p = 0.037). The proportion of patients with hospitalization due to COPD exacerbations in patients who used SPIRIVA HANDIHALER compared to placebo was 7.0% vs. 9.5%, respectively; OR = 0.72; 95% CI = 0.51, 1.01; p = 0.056.

Where the research disagrees

Whether tiotropium delivered by the Respimat soft-mist inhaler increases the risk of death

• Singh, Loke, Enright and Furberg, meta-analysis of five randomised trials (BMJ 2011), fixed-effect meta-analysis of 5 placebo-controlled randomised trials, 90 deaths in 3,686 versus 47 in 2,836, I2=0%, with sensitivity analyses: This meta-analysis explains safety concerns by regulatory agencies and indicates a 52% increased risk of mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease. (Source 12)
• Karner, Chong and Poole, Cochrane review (2014 update), systematic review of 22 trials with a prespecified subgroup analysis by device (test for subgroup differences P=0.01); the same review found no overall mortality difference, Peto OR 0.98 (0.86 to 1.11): with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%) (Source 2)
• Wise and colleagues, TIOSPIR randomised trial (NEJM 2013), randomised, double-blind, parallel-group non-inferiority trial in 17,135 patients, mean follow-up 2.3 years; funded by Boehringer Ingelheim. Note the comparator was HandiHaler, not placebo, so it answers a different question from the placebo-controlled meta-analysis: Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 μg in patients with COPD. (Source 19)

Whether inhaled anticholinergics as a class raise cardiovascular risk in COPD

• Singh, Loke and Furberg, meta-analysis of 17 trials (JAMA 2008), fixed-effects meta-analysis of 17 randomised trials in 13,645 patients, composite RR 1.60 (1.22-2.10), I2=0%; includes ipratropium as well as tiotropium: Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD. (Source 13)
• Wise and colleagues, TIOSPIR (NEJM 2013), 17,135-patient randomised trial that specifically assessed cardiovascular safety, including in patients with stable cardiac disease: Causes of death and incidences of major cardiovascular adverse events were similar in the three groups. (Source 19)
• The US label, section 14 Clinical Studies (version effective 10 November 2025), regulatory position summarising the 4-year trial and the head-to-head device comparison: In the 4-year placebo-controlled lung-function trial described above, all-cause mortality compared to placebo was assessed. There were no significant differences in all-cause mortality rates between SPIRIVA HANDIHALER and placebo. (Source 21)

How much

• Reference intake: No reference intake exists; this is a prescription inhaler and the dose is set by the prescriber. As a position, the label (effective 10 November 2025) states the COPD regimen as two inhalations of the powder from one capsule once daily with the HandiHaler device, and not more than one dose in 24 hours. (Source 22)
• Upper limit: The label's stated maximum is one dose in 24 hours: 'Do not take more than one dose in 24 hours.' For asthma with the Respimat the stated dose is two inhalations of 1.25 micrograms per actuation once daily, total 2.5 micrograms. There is no nutritional upper limit. (Source 22)
• Studied: The 4-year UPLIFT trial gave 18 micrograms once daily by HandiHaler, or placebo, to 5,993 people with COPD. (Source 3)
• Studied: TIOSPIR randomised 17,135 people to Respimat 2.5 or 5 micrograms once daily, or HandiHaler 18 micrograms once daily, for a mean 2.3 years. (Source 19)
• Studied: The two replicate asthma trials gave a total dose of 5 micrograms once daily by soft-mist inhaler for 48 weeks on top of inhaled steroid plus long-acting beta-agonist. (Source 4)
• Studied: The Cochrane COPD review pooled 19 trials of 18 micrograms once daily by Handihaler and 3 trials of 5 or 10 micrograms once daily by Respimat, for three months to four years. (Source 2)

A common belief, and what the research shows

The belief: An inhaler like this slows down COPD, so taking it for years protects your lungs from getting worse.

What the research shows: That is exactly what the 4-year UPLIFT trial in 5,993 people was designed to test, and it did not find it. The absolute improvement in FEV1 was real and held up for four years, but the rate of decline was the same as on placebo: After day 30, the differences between the two groups in the rate of decline in the mean FEV(1) before and after bronchodilation were not significant. The second misconception is the opposite error - that the 2011 Respimat mortality signal settles the matter. The 17,135-patient TIOSPIR trial that followed found Respimat non-inferior to HandiHaler for death, so the honest summary is that a placebo-controlled signal existed and a head-to-head trial did not reproduce a device difference.

Questions and answers

What is it?

An inhaled bronchodilator taken once a day for COPD, and for asthma in people aged 6 and over. It is a long-acting muscarinic antagonist, structurally related to atropine. Two devices exist and they are not interchangeable in the evidence: the HandiHaler dry-powder capsule delivering 18 micrograms, and the Respimat soft-mist spray delivering 2.5 or 5 micrograms. (Source 23)

What does it do in the body?

It blocks muscarinic receptors on the smooth muscle of the airways, mainly the M3 subtype, so the airways relax and open. The block is competitive and reversible but comes off slowly, which is why one inhalation keeps working for more than 24 hours. The effect is mostly local to the lung. (Source 1)

Is it good or bad for you?

In COPD it is on balance good: a Cochrane review of 22 trials found better quality of life and fewer exacerbations, needing 16 people treated for a year to prevent one having an exacerbation. It is not a disease-modifier - UPLIFT showed no slowing of lung-function decline. The harms are the anticholinergic ones, with dry mouth in 16 percent on drug versus 3 percent on placebo in the one-year trials, plus warnings on glaucoma and urinary retention. And there is an unresolved safety history: a 2011 meta-analysis found 52 percent higher mortality with the soft-mist inhaler against placebo, which the later 17,135-patient head-to-head trial did not reproduce. (Source 2)

How do you get more of it?

Only by prescription; no food or supplement contains it. The dose is fixed by the device and the label, and more is not better - the label states not more than one dose in 24 hours. In asthma it is also worth knowing it builds up: maximum benefit in lung function can take 4 to 8 weeks of daily dosing, so an apparent lack of effect in the first fortnight is expected. (Source 24)

If it is harmful, what reduces it?

Stopping the inhaler clears it; the drug is predominantly excreted by the kidneys, which is why people with moderate to severe renal impairment (creatinine clearance under 60 mL/min) are watched more closely for anticholinergic effects. If a hypersensitivity reaction or paradoxical bronchospasm occurs the label says to stop at once. There is no antidote described. (Source 7)

Why might someone be low in it or missing it?

Not applicable in the usual sense - nobody is naturally low in a synthetic drug. What goes wrong in practice is delivery: the HandiHaler capsule must be pierced and inhaled through the device, and the label states the capsules must not be swallowed because the intended effect on the lungs will not be obtained. Inhaler technique, and in young children the need for a valved holding chamber with a facemask, are the practical reasons the drug fails to reach the lung. (Source 22)

Which whole foods contain it or feed it?

None. Tiotropium is synthetic and is not present in any food. The only food-related point in the label is an excipient one: the HandiHaler capsules are blended with lactose, which carries milk protein, so the label advises caution in people with severe milk-protein hypersensitivity. No food or supplement interaction is documented. (Source 9)

What happens if you do not have it?

Nothing is lost physiologically. What returns is the symptom burden: the lung-function gain is measured at the end of treatment and is not banked, and the exacerbation benefit is a while-taking-it effect - in the 6-month Veterans Affairs trial 32.3 percent of people on placebo had an exacerbation against 27.9 percent on the drug. It is also not a rescue medicine, so its absence during an acute attack is not what a reliever inhaler would cover. (Source 18)

How can you test for it?

There is no blood test for tiotropium in routine use. What gets measured is the effect: spirometry, specifically trough (pre-dose) FEV1 and peak FEV1, which is how every trial judged it. In the one-year trials the peak improvement after a week of once-daily dosing was 0.28 to 0.31 litres relative to baseline, and effect was maintained for 24 hours after a dose. Spirometry is reproducible but effort-dependent and needs trained coaching, so a single poor-quality test can mislead. (Source 11)

References

1. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 12.1 Mechanism of Action. 2025. Read the source
2. The Cochrane database of systematic reviews. Tiotropium versus placebo for chronic obstructive pulmonary disease.. 2014. PMID 25046211, DOI 10.1002/14651858.CD009285.pub3. Read the source
3. The New England journal of medicine. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.. 2008. PMID 18836213, DOI 10.1056/NEJMoa0805800. Read the source
4. The New England journal of medicine. Tiotropium in asthma poorly controlled with standard combination therapy.. 2012. PMID 22938706, DOI 10.1056/NEJMoa1208606. Read the source
5. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA RESPIMAT label, section 8.4 Pediatric Use. 2026. Read the source
6. The Cochrane database of systematic reviews. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.. 2015. PMID 26196545, DOI 10.1002/14651858.CD011437.pub2. Read the source
7. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 5.1 Not for Acute Use. 2025. Read the source
8. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 7.2 Anticholinergics. 2025. Read the source
9. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 7.1 Sympathomimetics, Methylxanthines, Steroids. 2025. Read the source
10. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 5.2 Immediate Hypersensitivity Reactions. 2025. Read the source
11. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 14 CLINICAL STUDIES - 4-Year Effects on Lung Function. 2025. Read the source
12. BMJ (Clinical research ed.). Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.. 2011. PMID 21672999, DOI 10.1136/bmj.d3215. Read the source
13. JAMA. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.. 2008. PMID 18812535, DOI 10.1001/jama.300.12.1439. Read the source
14. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 6.1 Clinical Trials Experience, Table 1 (adverse reactions >=3% in the 1-year placebo-controlled and ipratropium-controlled trials). 2025. Read the source
15. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 6.1 Clinical Trials Experience - 4-Year Trial. 2025. Read the source
16. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA RESPIMAT label, section 6.2 Clinical Trials Experience in Asthma, Table 2 (adverse reactions >2% in adults, SPIRIVA RESPIMAT 2.5 mcg versus placebo). 2026. Read the source
17. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 5.4 Worsening of Narrow-Angle Glaucoma. 2025. Read the source
18. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 14 CLINICAL STUDIES - Exacerbations. 2025. Read the source
19. The New England journal of medicine. Tiotropium Respimat inhaler and the risk of death in COPD.. 2013. PMID 23992515, DOI 10.1056/NEJMoa1303342. Read the source
20. The Cochrane database of systematic reviews. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.. 2016. PMID 26798035, DOI 10.1002/14651858.CD011721.pub2. Read the source
21. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 14 CLINICAL STUDIES - All-Cause Mortality. 2025. Read the source
22. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 2 DOSAGE AND ADMINISTRATION. 2025. Read the source
23. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA HANDIHALER label, section 1 INDICATIONS AND USAGE. 2025. Read the source
24. DailyMed (US FDA Structured Product Label), Boehringer Ingelheim Pharmaceuticals, Inc.. SPIRIVA RESPIMAT label, section 2.2 Asthma. 2026. Read the source